Latest news with #brensocatib
Yahoo
a day ago
- Business
- Yahoo
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
3 days ago
- Business
- Yahoo
Insmed (INSM) Soars After Raising $650 million
We recently published a list of . In this article, we are going to take a look at where Insmed Inc. (NASDAQ:INSM) stands against other best-performing stocks on Wednesday. Insmed jumped for a second day on Wednesday, adding 7.75 percent to close at $97.98 apiece following plans to raise $650 million through the issuance of more shares. In a copy of the prospectus, Insmed Inc. (NASDAQ:INSM) said proceeds from the offer will be used to fund the continued research and development, pre-commercial, and commercialization of its drug candidates brensocatib, Arikayce, treprostinil palmitil inhalation powder (TPIP), and INSI201, among others. The remaining balance will be allocated for general corporate purposes, including business expansion. Additionally, Insmed Inc. (NASDAQ:INSM) granted its underwriters the option to purchase up to an additional $97.5 million of its common stock. The fundraising program followed Insmed Inc.'s (NASDAQ:INSM) promising results from the phase 2 trial of its pulmonary arterial hypertension (PAH) treatment, TPIP. According to the company, the phase 2 trial achieved its primary and secondary goals for the treatment of reducing blood pressure in the lungs and improving exercise capacity in patients. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Following the announcements, four investment companies, namely BofA Securities, RBC, Morgan Stanley, and Mizuho, gave a 'buy' recommendation and 'overweight' rating on its stock at a price target ranging from $102 to $110. Overall, INSM ranks 10th on our list of best-performing stocks on Wednesday. While we acknowledge the potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
